Duopharma Biotech Bhd (XKLS:7148) YoY EBITDA Growth: 26.09% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:7148 Duopharma Biotech Bhd XKLS:7148
87 GF Score
Price RM1.16
GF Value RM1.50
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd YoY EBITDA Growth?

Duopharma Biotech Bhd XKLS:7148 -0.85% 87 YoY EBITDA Growth is 26.09% as of Jun. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 87/100 and a GF Value™ of RM1.50 (Modestly Undervalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Duopharma Biotech Bhd's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 26.09%.

Duopharma Biotech Bhd's EBITDA per Share for the three months ended in Jun. 2026 was RM0.06.

Duopharma Biotech Bhd YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd YoY EBITDA Growth Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.38 5.34 -5.80 21.54 21.52

Duopharma Biotech Bhd Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.52 22.50 22.22 11.32 26.09
XKLS:7148
87GF Score
Duopharma Biotech Bhd XKLS:7148
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Duopharma Biotech Bhd's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.192-0.158)/ | 0.158 |
=21.52 %

Duopharma Biotech Bhd's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.058-0.046)/ | 0.046 |
=26.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 26.09% mean?
Duopharma Biotech Bhd (XKLS:7148) has a YoY EBITDA Growth of 26.09% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's YoY EBITDA Growth too high?
Duopharma Biotech Bhd's current YoY EBITDA Growth is 26.09%. Overall, Duopharma Biotech Bhd has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's YoY EBITDA Growth compare to ZTS and UTHR?
Duopharma Biotech Bhd's YoY EBITDA Growth of 26.09% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current YoY EBITDA Growth is 26.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.50, compared to a current price of RM1.16 — trading 22.7% below its estimated fair value. The current YoY EBITDA Growth is 26.09%. Duopharma Biotech Bhd's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current YoY EBITDA Growth is 26.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.16 is trading 22.7% below its estimated GF Value™ of RM1.50. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • YoY EBITDA Growth: 26.09%
  • GF Value™: RM1.50 vs. price of RM1.16 (22.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
87GF Score

Get the complete analysis for XKLS:7148

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.16
Price
RM1.50
GF Value